Shreem Muppetti
Analyst
Investigator, KAISA-6 Phase II Trial
Equibles does not estimate personal net worth.
About Shreem Muppetti
Shreem Muppetti is recorded as Analyst at Investigator, KAISA-6 Phase II Trial. Shreem Muppetti has spoken on 1 investor event across 1 company, most recently for Kyverna Therapeutics, Inc. on April 22, 2026. The companies whose calls Shreem Muppetti spoke on are classified in the Healthcare sector.
Shreem Muppetti on recent calls
“These results are unprecedented and exciting for the field. We've seen even deeper reduction in MgADL-QMG compared to previously approved therapies. The MgADL-QMG reduction seems sustained and further reduces as you go up to week 52.”
Affiliation history
-
Investigator, KAISA-6 Phase II Trial
Analyst
Transcript header (unverified)
Current